Qualitative Analysis of the Content Validity of the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) in Schizophrenia: A Multi-Stakeholder Perspective

The US Food and Drug Agency (FDA) requires clinical trials targeting cognitive impairment associated with schizophrenia (CIAS) to demonstrate the functional relevance of cognitive improvements by employing a functional co-primary measure. Although quantitative evidence supports the suitability of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Horan, William P, Depp, Colin A, Hurst, Samantha, Linthicum, Jared, Vargas, Gabriela, Klein, Hans, Keefe, Richard S E, Harvey, Philip D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664622/
https://www.ncbi.nlm.nih.gov/pubmed/38026054
http://dx.doi.org/10.1093/schizbullopen/sgad012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664622/
https://www.ncbi.nlm.nih.gov/pubmed/38026054
http://dx.doi.org/10.1093/schizbullopen/sgad012

Ejemplares similares